Strategic Developments in the Worldwide Blood Plasma Industry
Complex manufacturing procedures and concerns regarding the safety of synthetic colloids can limit widespread adoption, particularly in developing economies with budget constraints.
marketing researcher The global colloids (blood plasma) market size was valued at USD 3.61 billion in 2025 and is projected to grow from USD 3.80 billion in 2026 to USD 5.75 billion by 2034, exhibiting a CAGR of 5.3% during the forecast period (2026–2034). Increasing prevalence of chronic diseases, growing number of surgical procedures, and rising adoption of plasma-derived products in critical care are supporting market expansion worldwide.
Key Highlights
- Largest Region: North America
- Fastest-Growing Region: Asia-Pacific
- Largest Segment by Type: Natural Type Colloids
- Fastest-Growing Segment by Type: Synthetic Type Colloids
- Largest Segment by Application: Massive Blood or Plasma Loss
- Fastest-Growing Segment by Application: Hypovolemic Shock
Market Size Overview
| Market Metric | Value |
|---|---|
| Base Year | 2025 |
| Market Size 2025 | USD 3.61 Billion |
| Estimated Market Size 2026 | USD 3.80 Billion |
| Forecast Year | 2034 |
| Market Size 2034 | USD 5.75 Billion |
| CAGR (2026-2034) | 5.3% |
Market Dynamics
Driver
The increasing burden of chronic diseases and age-related disorders has significantly increased demand for blood plasma products and colloid solutions. Growing incidences of trauma cases, liver disorders, immune deficiencies, and cardiovascular diseases are encouraging healthcare providers to utilize plasma-based therapies and volume expanders for effective patient management. Moreover, rising surgical procedures globally continue to generate demand for colloids used for maintaining blood circulation and blood pressure during critical care treatments.
Restraint
Despite steady growth, the market faces challenges associated with high production costs and stringent regulatory requirements governing plasma collection and processing. Complex manufacturing procedures and concerns regarding the safety of synthetic colloids can limit widespread adoption, particularly in developing economies with budget constraints.
Opportunities
Technological advancements in plasma fractionation, improved blood collection infrastructure, and increasing investments in healthcare systems are creating lucrative opportunities for market participants. In addition, continuous product innovations and the development of advanced plasma-derived therapies are expected to expand the application scope of colloids, particularly across emerging economies in Asia-Pacific and Latin America.
Top Market Players
- CSL Behring
- Baxter
- Grifols S.A.
- Octapharma
- Shanghai RAAS Blood Products Co. Ltd.
- Shandong Taibang Biological Products Co. Ltd. (China Biologic Products Inc.)
- Hualan Biological Engineering Inc.
- Chengdu Rongsheng Pharmaceuticals Co., Ltd.
- China National Pharmaceutical Group Corporation
- ADMA Biologics Inc.
Market Segmentation
By Type
- Natural Type Colloids
- Synthetic Type Colloids
By Application
- Extensive Burns
- Massive Blood or Plasma Loss
- Hypovolemic Shock
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- Latin America
Unlock Full Report Insights and Strategic Analysis: https://straitsresearch.com/report/colloids-blood-plasma-market
Comprehensive analysis provides detailed market trends, competitive landscape, growth opportunities, regional outlook, and strategic recommendations for industry participants seeking expansion opportunities in the global colloids (blood plasma) market.
About Us
Straits Research is a leading market research and market intelligence organization specializing in research, analytics, and advisory services while delivering actionable business insights and market research reports to organizations worldwide.
Contact Us
U.S.: +1 646 905 0080
U.K.: +44 203 695 0070
